Rossari Biotech Limited
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printi… Read more
Rossari Biotech Limited (ROSSARI) - Net Assets
Latest net assets as of September 2025: ₹12.51 Billion INR
Based on the latest financial reports, Rossari Biotech Limited (ROSSARI) has net assets worth ₹12.51 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹20.88 Billion) and total liabilities (₹8.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹12.51 Billion |
| % of Total Assets | 59.94% |
| Annual Growth Rate | 44.61% |
| 5-Year Change | 190.0% |
| 10-Year Change | N/A |
| Growth Volatility | 40.31 |
Rossari Biotech Limited - Net Assets Trend (2017–2025)
This chart illustrates how Rossari Biotech Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rossari Biotech Limited (2017–2025)
The table below shows the annual net assets of Rossari Biotech Limited from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹11.85 Billion | +13.14% |
| 2024-03-31 | ₹10.48 Billion | +14.49% |
| 2023-03-31 | ₹9.15 Billion | +13.66% |
| 2022-03-31 | ₹8.05 Billion | +96.97% |
| 2021-03-31 | ₹4.09 Billion | +42.59% |
| 2020-03-31 | ₹2.87 Billion | +131.54% |
| 2019-03-31 | ₹1.24 Billion | +42.18% |
| 2018-03-31 | ₹870.80 Million | +40.49% |
| 2017-03-31 | ₹619.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rossari Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1560.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹6.97 Billion | 58.81% |
| Common Stock | ₹110.73 Million | 0.93% |
| Other Comprehensive Income | ₹21.14 Million | 0.18% |
| Other Components | ₹4.75 Billion | 40.08% |
| Total Equity | ₹11.85 Billion | 100.00% |
Rossari Biotech Limited Competitors by Market Cap
The table below lists competitors of Rossari Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gotland Rederi AB Series B
ST:GOTL-B
|
$86.37 Million |
|
Celtic plc
PINK:CLTFF
|
$86.38 Million |
|
KlaraBo Sverige AB Series B
ST:KLARA-B
|
$86.41 Million |
|
EVA Precision Industrial Holdings Limited
F:GZT
|
$86.41 Million |
|
Ubiquoss Inc
KQ:264450
|
$86.28 Million |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
$86.27 Million |
|
Summit Bank Group Inc
PINK:SBKO
|
$86.26 Million |
|
Sea1 Offshore Inc.
OL:SEA1
|
$86.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rossari Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,477,280,000 to 11,854,490,000, a change of 1,377,210,000 (13.1%).
- Net income of 1,363,780,000 contributed positively to equity growth.
- Dividend payments of 27,650,000 reduced retained earnings.
- New share issuances of 50,670,000 increased equity.
- Other comprehensive income decreased equity by 14,220,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.36 Billion | +11.5% |
| Dividends Paid | ₹27.65 Million | -0.23% |
| Share Issuances | ₹50.67 Million | +0.43% |
| Other Comprehensive Income | ₹-14.22 Million | -0.12% |
| Other Changes | ₹4.63 Million | +0.04% |
| Total Change | ₹- | 13.14% |
Book Value vs Market Value Analysis
This analysis compares Rossari Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 33.10x to 1.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | ₹12.81 | ₹423.95 | x |
| 2018-03-31 | ₹17.99 | ₹423.95 | x |
| 2019-03-31 | ₹25.58 | ₹423.95 | x |
| 2020-03-31 | ₹58.12 | ₹423.95 | x |
| 2021-03-31 | ₹78.81 | ₹423.95 | x |
| 2022-03-31 | ₹145.93 | ₹423.95 | x |
| 2023-03-31 | ₹165.33 | ₹423.95 | x |
| 2024-03-31 | ₹189.37 | ₹423.95 | x |
| 2025-03-31 | ₹214.09 | ₹423.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rossari Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.50%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.56%
- • Asset Turnover: 1.10x
- • Equity Multiplier: 1.60x
- Recent ROE (11.50%) is below the historical average (19.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 23.05% | 6.08% | 1.79x | 2.11x | ₹80.86 Million |
| 2018 | 29.17% | 8.72% | 1.77x | 1.89x | ₹166.95 Million |
| 2019 | 36.90% | 8.90% | 2.05x | 2.02x | ₹333.02 Million |
| 2020 | 22.76% | 10.91% | 1.27x | 1.64x | ₹365.85 Million |
| 2021 | 19.62% | 11.34% | 1.26x | 1.37x | ₹393.43 Million |
| 2022 | 12.13% | 6.59% | 1.18x | 1.56x | ₹171.58 Million |
| 2023 | 11.72% | 6.48% | 1.21x | 1.49x | ₹157.40 Million |
| 2024 | 12.47% | 7.14% | 1.16x | 1.50x | ₹259.16 Million |
| 2025 | 11.50% | 6.56% | 1.10x | 1.60x | ₹178.33 Million |
Industry Comparison
This section compares Rossari Biotech Limited's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $2,571,777,102
- Average return on equity (ROE) among peers: 15.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rossari Biotech Limited (ROSSARI) | ₹12.51 Billion | 23.05% | 0.67x | $86.31 Million |
| Aarti Industries Limited (AARTIIND) | $8.75 Billion | 18.56% | 2.05x | $1.01 Billion |
| Aarti Surfactants Limited (AARTISURF) | $2.18 Billion | 9.78% | 0.94x | $15.14 Million |
| ABM International Limited (ABMINTLLTD) | $214.51 Million | 3.09% | 0.89x | $294.24K |
| ACUTAAS CHEMICALS LTD (ACUTAAS) | $5.94 Billion | 14.02% | 0.29x | $247.08K |
| Advanced Enzyme Technologies Limited (ADVENZYMES) | $984.09 Million | 34.30% | 2.55x | $95.16 Million |
| Agarwal Industrial Corporation Limited (AGARIND) | $739.40 Million | 9.29% | 0.98x | $26.89 Million |
| Alkali Metals Limited (ALKALI) | $513.80 Million | 2.54% | 0.73x | $1.88 Million |
| Alkyl Amines Chemicals Limited (ALKYLAMINE) | $3.79 Billion | 22.71% | 1.01x | $204.91 Million |
| Ami Organics Limited (AMIORG) | $107.73 Million | 26.58% | 2.59x | $704.27 Million |
| Anupam Rasayan India Limited (ANURAS) | $2.50 Billion | 13.94% | 1.53x | $318.75 Million |